The new company will separate the fast-growing eye business from Bausch Health’s pharmaceutical business, the report said. The initial public offering values the company at $8.4 billion.
The spinoff has been planned since at least 2020, the report said.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.